Study says widely reported side effect of chemotherapy may be overestimated
(http://www.interscience.wiley.com/cancer - newsroom) on June 21, 2004.
While breast cancer remains one of the most common cancers, breakthroughs in the use of chemotherapy protocols with surgery have led to improved survival. However, previous studies have reported these drugs may be linked to permanent cognitive deficits, sometimes called "chemobrain," a side effect that could affect the decision to use chemotherapy for women wanting to return to academic, occupational and social pursuits.
Until now, studies linking chemotherapy to cognitive decline have looked only at post treatment neurocognitive function, without comparing to pre-treatment function. In the first prospective study to characterize cognitive abilities of breast cancer patients before adjuvant chemotherapy, Dr. Christina A. Meyers and colleagues from the University of Texas M. D. Anderson Cancer Center collected neuropsychological profiles from 84 women with noninvasive breast cancer prior to their treatment with chemotherapy.
Surprisingly, 35 percent of the women demonstrated baseline cognitive impairment with significant deficits in verbal learning and memory prior to chemotherapy. Psychomotor processing speed and attention, non-verbal memory, naming, complex visual tasks and hand fine motor dexterity also trended toward significant impairment compared to the controls.
"Given the current documentation of objective cognitive impairment prior to adjuvant systemic therapy," conclude the authors, the conclusions of studies reporting high frequencies of cognitive impairment "may overestimate the true incidence of declines in cognitive function secondary to chemotherapy" and dismiss all too easily the impact of cancer on neuropsychological function.
Article: "'Chemobrain' in Breast Carcinoma? A Prologue,"
Jeffrey S. Wefel,Renato Lenzi, Richard Theriault, Aman U.
Buzdar, Scott Cruickshank, and Christina A. Meyers, CANCER;
Published Online: June 21, 2004 (DOI: 10.1002/cncr.20393);
Print Issue Date: August 1, 2004.
For a copy of this paper, please contact David Greenberg at
201-748-6484 or by email at dgreenbe@wiley.com.
About John Wiley & Sons, Inc.
Founded in 1807, John Wiley & Sons, Inc., provides must- have content and services to customers worldwide. Our core businesses include scientific, technical, and medical journals, encyclopedias, books, and online products and services; professional and consumer books and subscription services; and educational materials for undergraduate and graduate students and lifelong learners. Wiley has publishing, marketing, and distribution centers in the United States, Canada, Europe, Asia, and Australia. The company is listed on the New York Stock Exchange under the symbols JWa and JWb. Wiley's Internet site can be accessed at http://www.wiley.com.
Contact: David Greenberg
(201) 748-6484
dgreenbe@wiley.com
Studiul afirmã larg raportate reacþii adverse ale chimioterapiei pot fi supraestimat - Study says widely reported side effect of chemotherapy may be overestimated - articole medicale engleza - startsanatate